Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation

References

• Bougie O, Weberpals JI. Clinical considerations of BRCA1 and BRCA2 mutation carriers: a review. Int J Surg Oncol 2011;2011:374012
   PubMedGoogle Scholar
• King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer, risks due to inherited mutation in BRCA1 and BRCA2. Science 2003;302:643–6
   PubMed Web of Science ®Google Scholar
• Girolimetti G, Perrone A, Santini D. BRCA-associated ovarian cancer – from molecular genetics to risk management. Biomed Res Int 2014;2014:787–96
   Web of Science ®Google Scholar
• Antoniou A, Pharoah PDP, Narod S. Average risks of breast and ovarian cancer associated with BRCA1 and BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;5:1117–30
   Web of Science ®Google Scholar
• Satagopan JM, Boyd J, Kauff ND. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutation. Clin Cancer Res 2002;8:3776–81
   PubMed Web of Science ®Google Scholar
• Lakhani SR, Van De Vijver MJ, Jacquemier J. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2 and P53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310–18
   PubMed Web of Science ®Google Scholar
• Foulkes WD, Kelly Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA-1 and BRCA-2 related breast cancer; the influence of age, grade and histologic type. Clin Cancer Res 2004;10:2029–34
   PubMed Web of Science ®Google Scholar
• Metcalfe KA, Ghaddirian P, Rosen B. Variation in rates of uptake of preventative options by Canadian women carrying the BRCA1 and BRCA2 genetic mutation. Open Med 2007;2:92–8
   Google Scholar
• Finch A, Evans G, Narod SA. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health 2012;5:543–55
   Google Scholar
• Finch A, Narod SA. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: a review. Maturitas 2011;70:261–5
   PubMed Web of Science ®Google Scholar
• Roccas WA, Grossardt BR, de Andrade M. Survival patterns after oophorectomy in premenopausal women: a population based cohort study. Lancet Oncol 2006;7:821–8
   PubMed Web of Science ®Google Scholar
• Sigal BM, Munoz DF, Kurian AW. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012;21:1066–77
   PubMed Web of Science ®Google Scholar
• American College of Obstetrics and Gynecology. ACOG Practice Bulletin Number 89. Elective and risk reducing salpingo-oophorectomy. Obstet Gynecol 2008;111:231–41
   PubMedGoogle Scholar
• Rabban JT, Krasik E, Chen LM, et al. Multistep level sections to detect occult fallopian tube carcinoma in risk reducing salpingo-oophorectomy from women with BRCA mutation: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol 2009;33:1878–85
   PubMed Web of Science ®Google Scholar
• Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009;16: 15–23
   PubMed Web of Science ®Google Scholar
• Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265–79
   PubMed Web of Science ®Google Scholar
• Rebbeck TF, Kauff ND, Domcheck SM. Meta-analysis of risk reduction estimates associated with risk reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80–9
   PubMed Web of Science ®Google Scholar
• Robson M, Henley M, Barakat R, et al. Quality of life in women at risk for ovarian cancer who have undergone risk reducing oophorectomy. Gynecol Oncol 2003;89:281–7
   PubMed Web of Science ®Google Scholar
• Chalberg J, Ashcroft L, Lallooo F, et al. Menopausal symptoms and bone health in women undergoing risk reducing bilateral salpingo-oophorectomy: significant bone issues in those not taking HRT. Br J Cancer 2011;105:22–7
   PubMed Web of Science ®Google Scholar
• Madalinska JB, van Beurden M, Bleiker EM, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 2006;24:3576–82
   PubMed Web of Science ®Google Scholar
• Cohen JV, Chiel L, Boghossian L, et al. Non-cancer endpoints in BRCA1/2 carriers after risk reducing salpingo-oophorectomy. Fam Cancer 2012;11:69–75
   PubMed Web of Science ®Google Scholar
• Guidozzi F. Hormone therapy in gynaecologic cancer survivors. Climacteric 2013;16:611–17
   PubMed Web of Science ®Google Scholar
• Guidozzi F. Estrogen replacement therapy for ovarian carcinoma survivors. A randomized controlled trial. Cancer 1999.;86:1013–18
   PubMed Web of Science ®Google Scholar
• Guidozzi F. Hormone replacement therapy and cancer. In Panay N, Briggs P, Kovacs G, eds, Managing the Menopause. Cambridge: Cambridge University Press, 2015:173–83
   Google Scholar
• Eisen A, Lubinsky J, Gronwald J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008;100:1361–7
   PubMed Web of Science ®Google Scholar
• Rebbeck TR, Freibel, Wagner T, et al. Effect of short term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study group. J Clin Oncol 2005;23:7804–10
   PubMed Web of Science ®Google Scholar
• Gabriell CA, Tigges-Cardwell J, Stopfer J, Erlichmann J, Nathanson K, Domchek SM. Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk reducing salpingo-oophorectomy. Fam Cancer 2009;1:23–8
   Web of Science ®Google Scholar
• Gadducci A, Biglia N, Cosio S, Sismondi P, Gennezzani AR. Gynecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. Gynecol Endocrinol 2010;26:568–77
   PubMed Web of Science ®Google Scholar
• Marchetti C, Iadarola R, Palaia I, et al. Hormone therapy in oophorectomized BRCA1/2 mutation carriers. Menopause 2014;21:763–7
   PubMed Web of Science ®Google Scholar